Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

2. Nkarta, Inc. (NASDAQ:NKTX)

Samsara BioCapital’s Stake Value: $56.58 million

Percentage of Samsara BioCapital’s 13F Portfolio: 8.87%

Number of Hedge Fund Holders: 10

Nkarta, Inc. (NASDAQ:NKTX) is a biotech company involved in developing and manufacturing allogeneic engineered natural killer (NK) cell therapies to fight against cancer.

In October 2021, the signing of a strategic platform license was announced between Nkarta, Inc. (NASDAQ:NKTX) and MaxCyte, Inc. (NASDAQ:MXCT). As per the agreement, Nkarta, Inc. (NASDAQ:NKTX) would have non-exclusive clinical and commercial rights to utilize MaxCyte’s Flow Electroporation technology and ExPERT platform.

As per the database of Insider Monkey, the leading shareholder in Nkarta, Inc. (NASDAQ:NKTX) is Peter Kolchinsky’s RA Capital Management with 5.6 million worth $155.87 million, making up 2.15% of the fund’s portfolio.